Hengrui Pharma's four subsidiaries have been approved to conduct clinical trials for drugs
Hengrui Pharma (01276.HK) announced that four subsidiaries received approval from the National Medical Products Administration for the issuance of the "Drug Clinical Trial Approval Notice," including: Shandong Shengdi HRS-1780 tablets for clinical trials in adult heart failure patients with left ventricular ejection fraction greater than or equal to 40%; Fujian Shengdi HRS9531 injection for clinical trials in metabolic-associated fatty liver disease; Ruishi Bio RSS0343 tablets for two clinical trials (chronic sinusitis without nasal polyps and chronic obstructive pulmonary disease); and Suzhou Shengdi SHR-A1811(sc) injection for clinical trials in patients with advanced solid tumors
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments